4.7 Article

Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01:05 allele in scleroderma patients with interstitial lung disease

期刊

RHEUMATOLOGY
卷 51, 期 10, 页码 1765-1774

出版社

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kes149

关键词

SSC; human leucocyte antigen; pulmonary fibrosis; microarray; peripheral blood mononuclear cells; gene expression; risk factor

资金

  1. Japanese Ministry of Health, Labor and Welfare
  2. Japanese Ministry of Education, Culture, Sports, Science and Technology

向作者/读者索取更多资源

Objective. Interstitial lung disease (ILD) is a serious complication of SSc. We aimed to identify markers associated with SSc-related ILD. Methods. RNA was prepared from the peripheral blood mononuclear cells of 14 SSc patients, divided into four different RNA pools according to the presence or absence of ILD and to the treatment, and subjected to microarray analysis. Real-time quantitative PCR was used to confirm the microarray results in 43 SSc patients, 42 autoimmune controls and 10 healthy controls. Genomic DNA samples were collected from 149 patients with SSc (70 in Hokkaido and 79 in Tokyo) who underwent a high-resolution CT for the evaluation of ILD and from 230 healthy controls. Genotyping was performed using sequence-specific primers. Results. The microarray analysis revealed HLA-DRB5 to be the only gene commonly up-regulated in patients with ILD compared with those without ILD in both comparison groups. High expression levels of HLA-DRB5 in SSc patients with ILD were confirmed by real-time quantitative PCR. The prevalence of HLA-DRB5 gene carriers increased in the SSc patients with ILD relative to those without ILD or to healthy controls in both cohorts. Among the four detected alleles, the HLA-DRB5*01:05 allele was significantly more frequent in SSc patients with ILD than in SSc patients without ILD or in healthy controls. These associations were confirmed in the second cohort. Conclusion. HLA-DRB5 was highly expressed in PBMCs from patients with SSc-related ILD. The HLA-DRB5*01:05 allele is a risk factor for ILD in patients with SSc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

Anti-ganglionic nicotinic acetylcholine receptor α3 subunit antibody as a potential biomarker associated with lupus enteritis

Kuniyuki Aso, Michihito Kono, Nobuya Abe, Yuichiro Fujieda, Masaru Kato, Tatsuya Atsumi

Summary: Anti-gAChR alpha 3 antibodies could be a predictive biomarker for the development or relapse of lupus enteritis in patients with systemic lupus erythematosus.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjogren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjogren's Syndrome Endocrinopathy) and ROSE II trials

Hiroto Tsuboi, Hirofumi Toko, Fumika Honda, Saori Abe, Hiroyuki Takahashi, Mizuki Yagishita, Shinya Hagiwara, Ayako Ohyama, Yuya Kondo, Kazuhisa Nakano, Yoshiya Tanaka, Toshimasa Shimizu, Hideki Nakamura, Atsushi Kawakami, Yuichiro Fujieda, Tatsuya Atsumi, Yasunori Suzuki, Mitsuhiro Kawano, Naoshi Nishina, Yuko Kaneko, Tsutomu Takeuchi, Hitomi Kobayashi, Masami Takei, Michihiro Ogasawara, Naoto Tamura, Yoshinari Takasaki, Kazuhiro Yokota, Yuji Akiyama, Toshihide Mimura, Kosaku Murakami, Tsuneyo Mimori, Shiro Ohshima, Naoto Azuma, Hajime Sano, Susumu Nishiyama, Isao Matsumoto, Takayuki Sumida

Summary: This study found that intravenous abatacept is effective in treating Sjogren's syndrome associated with rheumatoid arthritis. It improves both glandular and extraglandular involvements, as well as systemic disease activities and patient-reported outcomes. Adverse events were low, and adherence to abatacept was high.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication

Hiromu Ito, Keiichiro Nishida, Toshihisa Kojima, Isao Matsushita, Masayo Kojima, Shintaro Hirata, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masaaki Mori, Akio Morinobu, Atsuko Murashima, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Takeo Nakayama, Hisashi Yamanaka, Yutaka Kawahito, Masayoshi Harigai

Summary: This study aimed to update the clinical practice guidelines for the management of rheumatoid arthritis (RA) in Japan and develop an algorithm for non-drug and surgical treatments. The guidelines were updated using the Grading of Recommendations, Assessment, Development, and Evaluation method, and recommendations were developed based on 19 clinical questions regarding non-drug and surgical treatments. The study also created an original algorithm for the treatment of RA.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort

Eiichi Tanaka, Eisuke Inoue, Mai Abe, Kumiko Saka, Eri Sugano, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai

MODERN RHEUMATOLOGY (2022)

Article Rheumatology

Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication

Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Hiromu Ito, Toshihisa Kojima, Isao Matsushita, Keiichiro Nishida, Masaaki Mori, Atsuko Murashima, Hisashi Yamanaka, Takeo Nakayama, Masayo Kojima, Masayoshi Harigai

Summary: The Japan College of Rheumatology has updated the clinical practice guidelines for rheumatoid arthritis, providing a useful tool for rheumatologists, healthcare professionals, and patients to make shared decisions in various clinical situations.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis

Hisashi Yamanaka, Yoshiya Tanaka, Toshihiko Hibino, Gopalakrishnan Unmesh, Chirag Shah, Dhananjay Bakhle, Dimitris Stefanidis

Summary: YLB113 biosimilar demonstrated long-term safety and sustained efficacy in patients with rheumatoid arthritis. In a post-hoc analysis, patients treated with YLB113 experienced significantly lower incidence of injection-site reactions and injection-site erythema compared with the reference product.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Rheumatology

Predicting the response to pulmonary vasodilator therapy in systemic sclerosis with pulmonary hypertension by using quantitative chest CT

Keita Ninagawa, Masaru Kato, Yasuka Kikuchi, Hiroyuki Sugimori, Michihito Kono, Yuichiro Fujieda, Ichizo Tsujino, Tatsuya Atsumi

Summary: This study aimed to predict the response to pulmonary vasodilators in patients with SSc and PH. The results showed that quantitative chest computed tomography can well predict the response to vasodilators, suggesting its utility in differentiating the dominance of pulmonary vascular disease or interstitial lung disease.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Inhibitor of NF-κB Kinase Subunit ε Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation

Kohei Karino, Michihito Kono, Shuhei Takeyama, Yuki Kudo, Masatoshi Kanda, Nobuya Abe, Kuniyuki Aso, Yuichiro Fujieda, Masaru Kato, Kenji Oku, Olga Amengual, Tatsuya Atsumi

Summary: This study identified Ikbke as a potential therapeutic target for NPSLE based on its involvement in microglial activation and phagocytosis. Inhibition of IKBK epsilon improved cognitive function and suppressed microglial activation in MRL/lpr mice, suggesting its importance in the pathogenesis of NPSLE.

ARTHRITIS & RHEUMATOLOGY (2023)

Editorial Material Rheumatology

Homonymous hemianopsia and headache with mass-like lesion

Kuniyuki Aso, Yuichiro Fujieda, Tatsuya Atsumi

ANNALS OF THE RHEUMATIC DISEASES (2023)

Editorial Material Medicine, General & Internal

Reversible Diffuse Bronchial Wall Thickening

Kuniyuki Aso, Yuichiro Fujieda, Tatsuya Atsumi

INTERNAL MEDICINE (2023)

Article Rheumatology

Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study

Keita Ninagawa, Masaru Kato, Satonori Tsuneta, Suguru Ishizaka, Hideyuki Ujiie, Ryo Hisada, Michihito Kono, Yuichiro Fujieda, Yoichi M. Ito, Tatsuya Atsumi

Summary: Nintedanib has beneficial effects on cardiomyopathy associated with SSc, suggesting its anti-fibrotic effect may not be limited to the lungs.

RHEUMATOLOGY (2023)

Article Rheumatology

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Claudia A. Salinas, Anthony Louder, Jennifer Polinski, Tancy C. Zhang, Hannah Bower, Syd Phillips, Yufei Song, Emaan Rashidi, Rafia Bosan, Hsiu-Ching Chang, Nicole Foster, Bernice Gershenson, Hisashi Yamanaka, Mitsumasa Kishimoto, Yoshiya Tanaka, Peter Fischer, Baojin Zhu, Douglas Faries, Xiaodan Mai, Brett T. Doherty, Angela Grelaud, Nicolas H. Thurin, Johan Askling, Walter Deberdt

Summary: This study aimed to evaluate the safety of baricitinib compared to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients. The results showed an increased risk of venous thromboembolism (VTE) with baricitinib compared to TNFi treatment. Although the risk was slightly higher for major adverse cardiovascular events (MACE) and serious infection, the point estimates varied.

RHEUMATOLOGY AND THERAPY (2023)

Article Neurosciences

Dynamics of corticocortical brain functional connectivity relevant to therapeutic response to biologics in inflammatory arthritis

Kodai Sakiyama, Nobuya Abe, Yuichiro Fujieda, Khin K. Tha, Hisashi Narita, Kohei Karino, Masatoshi Kanda, Michihito Kono, Masaru Kato, Tatsuya Atsumi

Summary: Aberrant functional connectivity (FC) of the brain regions, evaluated by functional magnetic resonance imaging (fMRI), affects clinical courses in inflammatory arthritis (IA). The dynamic FC and corticocortical connectivity play a role in therapeutic responsiveness to biologics in IA patients. The frequent emergence of corticocortical connections is associated with clinical outcomes in IA.

CEREBRAL CORTEX (2023)

Letter Rheumatology

Hypothalamic lesion in a neuropsychiatric lupus patient with narcolepsy

H. Moriya, Y. Fujieda, O. Amengual, T. Kanbayashi, T. Atsumi

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Article Multidisciplinary Sciences

Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming

Kuniyuki Aso, Michihito Kono, Masatoshi Kanda, Yuki Kudo, Kodai Sakiyama, Ryo Hisada, Kohei Karino, Yusho Ueda, Daigo Nakazawa, Yuichiro Fujieda, Masaru Kato, Olga Amengual, Tatsuya Atsumi

Summary: The study reveals that itaconate can alter T cell function and impact the development of autoimmune diseases through modulation of metabolic and epigenetic programs. Itaconate inhibits Th17 cell differentiation and promotes Treg cell differentiation by suppressing glycolysis and oxidative phosphorylation. The metabolic changes induced by itaconate also affect chromatin accessibility, transcription factor binding, and gene expression in Th17 and Treg cell differentiation. Furthermore, the adoptive transfer of itaconate-treated Th17 cells can ameliorate autoimmune encephalomyelitis. These findings suggest that itaconate is a crucial metabolic regulator for Th17/Treg cell balance and can be a potential therapeutic agent for autoimmune diseases.

NATURE COMMUNICATIONS (2023)

暂无数据